<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673164</url>
  </required_header>
  <id_info>
    <org_study_id>SCIENCE</org_study_id>
    <nct_id>NCT02673164</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease</brief_title>
  <acronym>SCIENCE</acronym>
  <official_title>Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease - SCIENCE A European Multi-Centre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JKastrup</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the SCIENCE study is, in an international multicentre double-blind
      placebo-controlled study, to investigate efficacy of direct intra-myocardial injection of 100
      mio. allogeneic Cardiology Stem Cell Centre_adipose derived stem cells (CSCC_ASCs) in
      patients with reduced left ventricular Ejection Fraction (EF) (≤45%) and heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the SCIENCE study is, in an international multicentre double-blind
      placebo-controlled study, to investigate efficacy of direct intra-myocardial injection of 100
      mio. allogeneic Cardiology Stem Cell Centre_adipose derived stem cells (CSCC_ASCs) in
      patients with reduced left ventricular EF (≤45%) and heart failure.

      The primary objective is to investigate the regenerative capacity of direct intra-myocardial
      injection of 100 mio. allogeneic CSCC_ASCs in patients with reduced left ventricular EF
      (≤45%) and heart failure in a double-blind placebo-controlled design.

      A total of 138 patients with will be enrolled in the study and treated in a 2:1 randomization
      with either CSCC_ASC or placebo (saline).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>left ventricle end-systolic volume (LVESV)</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint is change in left ventricle end-systolic volume (LVESV) from baseline to 6 months follow-up measured by ECHO, MR and CT between CSCC_ASC and placebo treated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence and severity of serious adverse events and suspected unrelated serious adverse events 12 months follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CSCC_ASC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cardiology Stem Cell Centre_adipose derived stem cells (CSCC_ASC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSCC_ASC</intervention_name>
    <description>The stem cells will be injected directly into the myocardium using the NOGA XP system (BDS, US)</description>
    <arm_group_label>CSCC_ASC</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cardiology Stem Cell Centre_adipose derived stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 30 to 80 years of age

          2. Signed informed consent

          3. Chronic stable ischemic heart disease

          4. Symptomatic heart failure New York Heart Association (NYHA) class II-III

          5. EF ≤ 45% on echocardiography, Computerized Tomography (CT) or Magnetic Resonances
             Imaging (MRI) scan

          6. Plasma NT-pro-BNP &gt; 300 pg/ml (&gt; 35 pmol/L)

          7. Maximal tolerable heart failure medication

          8. Heart failure medication unchanged two months prior to inclusion. Changes in diuretics
             accepted.

          9. No option for percutaneous coronary intervention (PCI) or coronary artery bypass graft
             (CABG)

         10. Patients who have had PCI or CABG within six months of inclusion must have a new
             coronary angiography less than one month before inclusion or at least four months
             after the intervention to rule out early restenosis

         11. Patients cannot be included until three months after implantation of a cardiac
             resynchronisation therapy device (CRTD) and until 1 month after an ICD unit

        Exclusion Criteria:

          1. Heart Failure (NYHA class I or IV)

          2. Acute coronary syndrome with acute reversible elevation of CKMB or troponins, stroke
             or transitory cerebral ischemia within six weeks of inclusion. Constant elevated
             troponin due to renal failure, heart failure etc. do not exclude the patient.

          3. Other revascularisation treatment within four months of treatment

          4. If clinically indicated the patient should have a coronary angiography before
             inclusion

          5. Moderate to severe aortic stenosis (valve area &lt; 1.3 cm2) or valvular disease with
             option for surgery or interventional therapy.

          6. Aortic valve replacement with an artificial heart valve. However, a trans-septal
             treatment approach can be considered in these patients.

          7. If the patient is expected to be candidate for MitraClip therapy of mitral
             regurgitation in the 12 months follow-up period.

          8. Diminished functional capacity for other reasons such as: obstructive pulmonary
             disease (COPD) with forced expiratory volume (FEV) &lt;1 L/min, moderate to severe
             claudication or morbid obesity

          9. Clinical significant anaemia (haemoglobin &lt; 6 mmol/L), leukopenia (leucocytes &lt; 2
             109/L), leucocytosis (leucocytes &gt; 14 109/L) or thrombocytopenia (thrombocytes &lt; 50
             109/L)

         10. Reduced kidney function (estimated Glomerular Filtration Rate (eGFR) &lt; 30 ml/min)

         11. Left ventricular thrombus

         12. Anticoagulation treatment that cannot be paused during cell injections. Patients can
             continue with platelet inhibitor treatment

         13. Patients with reduced immune response or known anti‐HLA (human leukocyte antigen)
             antibodies

         14. History with malignant disease within five years of inclusion or suspected malignity -
             except treated skin cancer other than melanoma

         15. Pregnant women

         16. Other experimental treatment within four weeks of baseline tests

         17. Participation in another intervention trial

         18. Life expectancy less than one year

         19. Known hypersensitivity to Dimethyl sulfoxide (DMSO), penicillin and streptomycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Kastrup, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Kastrup, Professor MD</last_name>
    <phone>+4535452819</phone>
    <email>jens.kastrup@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Kastrup, MD DMSc</last_name>
      <phone>+4535452817</phone>
      <email>jens.kastrup@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Jens Kastrup, MD DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>JKastrup</investigator_full_name>
    <investigator_title>MD Professor</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>stem cell</keyword>
  <keyword>adipose derived stem cell</keyword>
  <keyword>Stem cell therapy</keyword>
  <keyword>ischemic heart disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data can be shared for Scientific collaboration</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

